No more annual flu shot? New target for universal influenza vaccine

CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing

Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission

Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need

Scientific Consortium Established by National Institutes of Health Provides Real-Time Risk Assessment of SARS-CoV-2 Variants on Immune Protection

"Immunity To Coronavirus Lingers For Months In Recovered Patients - Study"

"You're going to need more than one coronavirus shot. One dose of a vaccine probably won't be enough, experts say." - Aylin Woodward

Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19

Mount Sinai’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From U.S. Food and Drug Administration

Mount Sinai Developing an “End-to-End” Diagnostics Solution for COVID-19 That Incorporates Diagnosis, Treatment Selection, and Monitoring of Disease Course

"Researchers 'Encouraged' By early Data From Universal Flu Vaccine Study" - Marley Ghizzone